NO974956L - Therapeutic composition for arthritis - Google Patents

Therapeutic composition for arthritis

Info

Publication number
NO974956L
NO974956L NO974956A NO974956A NO974956L NO 974956 L NO974956 L NO 974956L NO 974956 A NO974956 A NO 974956A NO 974956 A NO974956 A NO 974956A NO 974956 L NO974956 L NO 974956L
Authority
NO
Norway
Prior art keywords
arthritis
agent
administration
inflammatory
acting
Prior art date
Application number
NO974956A
Other languages
Norwegian (no)
Other versions
NO974956D0 (en
Inventor
Haruhiko Makino
Takashi Sohda
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO974956L publication Critical patent/NO974956L/en
Publication of NO974956D0 publication Critical patent/NO974956D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det blir fremskaffet et farmasøytisk middel som viser hurtigvirkende og vedvarende anti-inflammatorisk analgesisk virkning mot kronisk artritis med lav fremtreden av bieffekter. En farmasøytisk sammensetning omfattende en kombinasjon av et quinolin-/quina- zolinserier profylaktisk/terapeutisk middel for artritis og hurtigvirkende anti-inflam- matorisk analgesisk middel omfattende (1) en cyklooksygenaseinhibitor, (2) et sentralt analgesika, (3) et steroid eller (4) et anti-inflammatorisk enzym-middel. Foreliggende preparat viser utmerkede effekter mot artritis fra administrasjon for å sikre stabil anti-inflammatorisk analgesisk virkning med lav fremtreden av bieffekter selv ved kronisk administrasjon, forutsatt at medikamentsammensetning, administrasjonsmetode og dose er passende valgt ifølge symptomene.A pharmaceutical agent is provided which shows fast-acting and sustained anti-inflammatory analgesic action against chronic arthritis with a low onset of side effects. A pharmaceutical composition comprising a combination of a quinoline / quinazoline series prophylactic / therapeutic agent for arthritis and fast-acting anti-inflammatory analgesic agent comprising (1) a cyclooxygenase inhibitor, (2) a central analgesic, (3) a steroid or ( 4) an anti-inflammatory enzyme agent. The present preparation shows excellent effects against arthritis from administration to ensure stable anti-inflammatory analgesic effect with low appearance of side effects even in chronic administration, provided that drug composition, administration method and dose are appropriately selected according to the symptoms.

NO974956A 1995-04-28 1997-10-27 Therapeutic composition for arthritis NO974956D0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP10631695 1995-04-28
JP27085695 1995-10-19
PCT/JP1996/001102 WO1996033717A1 (en) 1995-04-28 1996-04-24 Therapeutic composition for arthritis

Publications (2)

Publication Number Publication Date
NO974956L true NO974956L (en) 1997-10-27
NO974956D0 NO974956D0 (en) 1997-10-27

Family

ID=26446436

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974956A NO974956D0 (en) 1995-04-28 1997-10-27 Therapeutic composition for arthritis

Country Status (7)

Country Link
EP (1) EP0830133A1 (en)
KR (1) KR19990008148A (en)
AU (1) AU715358B2 (en)
CA (1) CA2216138A1 (en)
HU (1) HUP9801628A2 (en)
NO (1) NO974956D0 (en)
WO (1) WO1996033717A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262269B1 (en) 1997-02-04 2001-07-17 Trega Biosciences, Inc. 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries
AU8191998A (en) * 1997-02-04 1998-08-25 Trega Biosciences, Inc. 4-substituted-quinoline derivatives and 4-substitute-quinoline combinatorial libraries
JP3930428B2 (en) 2000-08-09 2007-06-13 エフ．ホフマン−ラ ロシュ アーゲー Quinoline derivatives as anti-inflammatory agents
CA2436739A1 (en) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68908459T2 (en) * 1988-04-26 1994-04-07 Asahi Glass Co Ltd Prepolymer composition, process for its preparation and its use.
US4968701A (en) * 1988-04-26 1990-11-06 E. I. Du Pont De Nemours And Company 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents
US5187180A (en) * 1990-07-26 1993-02-16 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists
TW232013B (en) * 1992-04-24 1994-10-11 Takeda Pharm Industry Co Ltd
NO940245D0 (en) * 1993-01-28 1994-01-24 Takeda Chemical Industries Ltd Quinoline or quinazoline derivatives, their preparation and use
US5641788A (en) * 1994-06-07 1997-06-24 Takeda Chemical Industries, Ltd. Quinoline derivatives and pharmaceutical composition containing them

Also Published As

Publication number Publication date
WO1996033717A1 (en) 1996-10-31
AU715358B2 (en) 2000-01-20
AU5513696A (en) 1996-11-18
HUP9801628A2 (en) 1999-01-28
EP0830133A1 (en) 1998-03-25
NO974956D0 (en) 1997-10-27
CA2216138A1 (en) 1996-10-31
KR19990008148A (en) 1999-01-25

Similar Documents

Publication Publication Date Title
AP1637A (en) Celecoxib compositions.
BR0013704A (en) Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular cases
NO922004D0 (en) ORAL PREPARATION FOR TREATMENT OF INFLAMMATORY GAS DISORDERS
NO305537B1 (en) Pharmaceutical preparation containing a defined lipid system and use of the lipid system
BR0012136A (en) Highly selective norepinephrine reabsorption inhibitors and methods of using them
SE9704870D0 (en) New pharmaceutical formulation I
ATE486840T1 (en) MODIFIED FORMS OF PHARMACEUTICALLY ACTIVE AGENTS AND USES THEREOF
WO1998019649A3 (en) Methods and compositions for inhibition of angiogenesis
RO116342B1 (en) Oral liquid pharmaceutical composition
BR9709838A (en) Administration regimen that provides a blood plasma profile of an h +, k + -atpase inhibitor oral pharmaceutical composition and the use of h +, k + -atpase inhibitor and processes to improve the inhibition of gastric acid secretion and the therapeutic effect on treatment of gastrointestinal disorders and to receive an extended plasma profile of an h +, k + -atpase inhibitor
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
BR9810520A (en) Factor xa inhibitor alone or in combination with an anti-platelet aggregator, against arterial thrombosis
WO2000033790A3 (en) Methods and compositions for prevention and treatment of arterial lesions with non-steroidal anti-inflammatory drugs
BR9813179A (en) Extended release formulation
ES2193233T3 (en) USE OF AMIODIPINE, A SALT OF THE SAME OR PHELODIPINE IN COMBINATION WITH AN ACE INHIBITOR IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF NON-ISCHEMICAL CONJUNCTIVE HEART FAILURE.
ES2126123T3 (en) USE OF CINEOL OR MENTHOL FOR THE TREATMENT OF ASTHMA.
BR9803233A (en) Preparation of a pharmaceutical combination of a sodium / hydrogen exchanger inhibitor and a drug for the treatment of cardiovascular diseases.
NO974956L (en) Therapeutic composition for arthritis
NO955084L (en) Estreno steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
NO990450L (en) Treatment of mental disorders
DK0862454T3 (en) CTLA-8 in combination with G-CSF or with G-CSF and IL-6 and use of CTLA-8 to treat infections
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
BR0012121A (en) Aminotetralin derivative for cardiovascular disease therapy
NO952234L (en) Transdermal administration system containing acetylsalicylic acid for antithrombosis therapy and cancer prevention
NO20050933L (en) Pravastatin pharmaceutical formulations and methods for their use